Research programme: hepatitis C virus therapy - Vernalis

Drug Profile

Research programme: hepatitis C virus therapy - Vernalis

Alternative Names: Hepatitis C virus therapy research programme - Vernalis

Latest Information Update: 07 Oct 2004

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vernalis
  • Class
  • Mechanism of Action Hepatitis C virus replication inhibitors; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 07 Oct 2004 Discontinued - Preclinical for Hepatitis C in United Kingdom (unspecified route)
  • 03 Oct 2003 RiboTargets has been integrated into British Biotech, which has merged with Vernalis Group to form Vernalis
  • 19 May 2003 RiboTargets has been acquired by British Biotech
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top